** Shares of drug development software provider Certara CERT.O rise 7.8% to $13.91
** Co expects prelim Q1 revenue of $106 million, above analysts' average estimate of $104.4 million as per data compiled by LSEG
** CERT expects 2025 revenue in the range of $415 million to $425 million, analysts' on average expect 2025 revenue of $419.8 million
** Co says its board has authorized a $100 million share repurchase program
** Separately, co launches an AI-enabled clinical assistance software to aid drug development that will reduce, refine, or replace animal testing
** The move comes after the U.S. FDA said it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with "human-relevant methods," including the use of AI-based models
** Including session's move, CERT up 31.2% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。